Charles Explorer logo
🇨🇿

Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial

Publikace na 1. lékařská fakulta |
2009

Tento text není v aktuálním jazyce dostupný. Zobrazuje se verze "en".Abstrakt

Vasomotor sympoms and bone loss are complications frequently induced by adjuvant treatment for breast cancer.Tibolone prevents both side-effects,but its effect on cancer recurrence is unknown. The aim ov this study was to show non-inferiority of tibolone to placebo regarding risk of recurrence in breast-cancer patients with climacteric complaints.